Anti-inflammatory agent


ES-62 is an immunomodulatory molecule derived from a parasitic nematode. It beneficially rebalances the immunological responses in disease situations by targeting signalling pathways at an early-stage. The compound itself is unsuitable for drug development.


Based upon the selective properties of ES-62,  scientists at Strathclyde have produced a series of small molecule analogues (SMAs) that are able to suppress inflammatory responses both in vitro and in vivo but only when aberrant hyper-inflammatory responses have been invoked. Thus, these compounds have the potential to provide a range of highly selective and safe drugs that do not immunocompromise the patient.

Like ES62 itself, the SMA’s are protective in models of arthritis, asthma, systemic lupus erythematosus (SLE).(including associated cardiovascular disease) and skin inflammation .

The SMAs cause partial degradation of myd88 within immune system cells in disease situations.  This project seeks to optimise the structures of new compounds to produce clinical candidates for the treatment of inflammatory diseases.

Key benefits

  • new class of anti-inflammatory agents with good druggability & easy synthetic access
  • broad portfolio of potential target diseases
  • selective immunomodulation as the patient remains 'immune competent' and able to fight off infections
  • compounds are both therapeutic & prophylactic


Markets & applications

This technology has the potential to treat many inflammatory-based conditions such as rheumatoid arthritis, SLE and asthma. Over 7 million individuals suffered with rheumatoid arthritis across the 10 major markets in 2014. There are 5.4 million people in the UK being treated for asthma, and  it is estimated that around 5 million people worldwide live with some degree of lupus condition.

Licensing & development

The technology is protected by a patent application filed by the University of Strathclyde and the University of Glasgow as GB0707724.1. Contact is welcomed from organisations interested in developing, licensing or exploiting this technology. For further information, please contact the RKES team, quoting reference 1647.

This project has received assistance from the Proof of Concept Programme managed by Scottish Enterprise. The Proof of Concept Programme supports the pre-commercialisation of leading-edge technologies emerging from Scotland's universities, research institutes and NHS Trusts.